Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

Inclusion Criteria: * Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures. * Complete baseline documentation sent to SKM CRS. * Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not allowed. In case of bilateral cancer the investigator has to decide prospectively which side will be evaluated for the primary endpoint. * Tumor lesion in the breast with a palpable size of \> 2 cm in maximum diameter. The leasion has to be measurable in two-dimensions by sonography. In case of inflammatory disease the extent of inflammation can be used as measurable lesion. The following tumor stages are eligible: * Palpable breast tumor size of \> 2 cm without involvement of the skin or muscle or evidence of inflammatory disease (T2-3). Clinical N0-2. (Study population I) * Primary tumor with clinical involvement of skin or muscle or clinically evidence of inflammatory breast cancer (T4 a-d) or clinical N3 including supraclavicular nodes. (Study population II). In patients with multifocal or multicentric breast cancer, the largest lesion should be measured. * Age \> 18 years. * Karnofsky Performance status index \> 80%. * Normal cardiac function must be confirmed by LVEF or shortening fraction (echocardiography or MUGA scan respectively) within 3 months prior to registration. The result must be above the normal limit of the institution. * Laboratory requirements (within 14 days prior to registration): * Hematology: * Neutrophils \> 2.0 x 109/L and * Platelets \> 100 x 109/L and * Hemoglobin \> 10 g/dL * Hepatic function: * Total bilirubin \< 1 x UNL and * ASAT (SGOT) and ALAT (SGPT) \< 2.5 x UNL and * Alkaline phosphatase \< 5 UNL. Patients with ASAT and/or ALAT \> 1.5 x UNL associated with alkaline phosphatase \> 2.5 x UNL are not eligible for the study. * Renal function: * Creatinine \< 175 µmol/L (2 mg/dL) * Tissue block centrally available for further biological tests. * Negative pregnancy test (urine or serum) within 14 days prior to registration for all women of childbearing potential. * Complete staging work-up within 3 months prior to registration. All patients must have bilateral mammography, breast ultrasound, breast MRI (optional), chest X-ray (PA and lateral), abdominal ultrasound and/or CT scan, and bone scan. In case of positive bone scan, bone X-ray is mandatory. Other tests may be performed as clinically indicated. * Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center which can be the Principal or the Co- Investigator's site. Exclusion Criteria: * Early breast cancer with a tumor size of \< 2 cm measured by palpation. * Patients with low or moderate risk. These patients are defined as having none of the following risk factors: Age \< 36 years, cT\> 5cm, ER and PR negative, cN+, or Grade III. * Evidence of distant metastasis. * Prior chemotherapy for any malignancy. * Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment. * Pre-existing motor or sensory neuropathy of a severity \> grade 2 by NCI criteria. * Other serious illness or medical condition: * previous malignant disease with a disease-free survival of less than 5 years (except CIS of the Cervix and non-melanomatous skin cancer. * congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year prior to study entry, uncontrolled arterial hypertension or high-risk uncontrolled arrhythmias. * history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent. * active uncontrolled infection. * active peptic ulcer, unstable diabetes mellitus. * Chronic treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose (\</= 20 mg methylprednisolone or equivalent). * Concurrent treatment with sex hormones. Prior treatment must be stopped before study entry. * Definite contraindications for the use of corticosteroids. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry. * Concurrent treatment with any other anti-cancer therapy. * Known hypersensitivity reaction to one of the investigational compounds or incorporated substances. * Male patients.